# Novo Nordisk A/S (NONOF)

> Source: Nexqual · https://nexqual.com/NONOF · data as of 2026-10-22 16:52 UTC · cite as "Nexqual, Novo Nordisk A/S (NONOF), nexqual.com/NONOF" · informational, not investment advice.

**Price:** USD 39.45 (+1.41% on the day) · last close of Oct 22, 2026; US market closed, not a live price. Prev close 38.9 · day 39.45–39.55 · 52w 34–64.75 · market cap $174B · PNK

## Key facts
- Analysts: None.
- Total return with dividends: 1Y -24.6% vs S&P 500 +14.4%; 5Y -20.9% vs S&P 500 +77.0%.
- Next earnings: 2026-11-04, EPS estimate USD —, revenue estimate $73.8B.

## Analysts
Consensus None.

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-23) | 5Y (from 2021-10-25) |
|---|---|---|
| Total return | -24.6% | -20.9% |
| S&P 500 (SPY) | +14.4% | +77.0% |
| Per year | -24.6% | -4.6% |
| Volatility (annualized) | 48.2% | 43.0% |
| Max drawdown | -43.7% (Jan 2026→Mar 2026) | -75.0% (Jun 2024→Mar 2026) |

## Peers (Drug Manufacturers - General)
PFE (Pfizer, Inc.) USD 29.96 -1.51% · GILD (Gilead Sciences, Inc.) USD 157.05 -0.09% · AMGN (Amgen Inc.) USD 441.32 -1.33% · BMY (Bristol-Myers Squibb Company) USD 61.53 -2.34% · AZN (AstraZeneca PLC) USD 171.1 -0.85% · NVS (Novartis AG) USD 151.14 -3.28%

## More
Full page: https://nexqual.com/NONOF · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Supply chain and relationships (SEC annual reports)


Other companies that name NONOF in their own reports (relationship from NONOF's side):

| Relationship | Company | Their filing | Sentence |
|---|---|---|---|
| competitor | iBio, Inc. (IBIO) | 10-K 2026-08-28 | "Our most significant competitors, among others, are fully integrated pharmaceutical companies such as Eli Lilly and Company, Novo Nordisk A/S, Amgen Inc., Bristol-Myers Squibb Company, Merck & Co., In…" |
| partner | Evotec SE (EVO) | 20-F 2026-04-08 | "Based on the strength of our molecular CKD patient database, we have built four partnerships in kidney diseases in the last almost ten years with prominent pharmaceutical companies such as Bayer, Vifo…" |
| competitor | Inventiva S.A. (IVA) | 20-F 2026-04-08 | "Furthermore, we face strong competition for enrollment from competitors who have received marketing authorization, such as Madrigal with Rezdiffra, and Novo Nordisk with Wegovy, and others who are con…" |
| partner | Innate Pharma SA (IPHA) | 20-F 2026-04-01 | "For example, Innate depends on its license agreement with Novo Nordisk A/S for the development and commercialization of monalizumab." |
| competitor | MANGOCEUTICALS, INC. (MGRX) | 10-K 2026-04-01 | "With our Mango SLIM product, we compete against the much larger pharmaceutical company Novo Nordisk., which offers the branded glucagon-like" |
| partner | OMEROS CORP (OMER) | 10-K 2026-03-31 | "● our expectations relating to the Asset Purchase and License Agreement (the "APLA"), by and between Omeros Corporation and Novo Nordisk Health Care AG ("Novo Nordisk"), including Novo Nordisk's antic…" |
| competitor | Alaunos Therapeutics, Inc. (TCRT) | 10-K 2026-03-31 | "Key competitors in the obesity space include (but are not limited to) companies such as Novo Nordisk, Eli Lilly, Amgen, Pfizer, Viking Therapeutics, Structure Therapeutics, and others." |
| competitor | Galmed Pharmaceuticals Ltd. (EOCN) | 20-F 2026-03-31 | "main competitors include Novo Nordisk with respect to Wegovy, which has typically been known for treating weight loss and diabetes and" |
| competitor | Rani Therapeutics Holdings, Inc. (RANI) | 10-K 2026-03-26 | "We face competition from current and future (generic and biosimilars) manufacturers of subcutaneous and IV injectable versions of our product candidates, such as AbbVie Inc., Eli Lilly and Company, Ja…" |
| competitor | Vivani Medical, Inc. (VANI) | 10-K 2026-03-26 | "Some of our competitors in the GLP-1 receptor agonist drug class include companies such as Novo Nordisk, AstraZeneca, and Eli Lilly." |
| competitor | Monte Rosa Therapeutics, Inc. (GLUE) | 10-K 2026-03-17 | "In addition to competition we face in developing TPD or MGD therapeutics, we will also face competition in the indications we expect to pursue with our GSPT1, NEK7, and CCNE1/CDK2 programs, including,…" |
| partner | Korro Bio, Inc. (KRRO) | 10-K 2026-03-12 | "our collaboration arrangement with Novo Nordisk A/S, or Novo Nordisk, including effects of the recent pause, and any future collaboration or licensing arrangements;" |
| competitor | Sagimet Biosciences Inc. (SGMT) | 10-K 2026-03-11 | "Our competitors include multinational pharmaceutical companies, specialized biotechnology companies and universities and other research institutions, including Altimmune, Inc., AstraZeneca, Boehringer…" |
| partner | vTv Therapeutics Inc. (VTVT) | 10-K 2026-03-10 | "In February 2007, we entered into an Agreement Concerning Glucokinase Activator Project with Novo Nordisk A/S (the "Novo License Agreement") whereby we obtained an exclusive, worldwide, sublicensable …" |
| competitor | Skye Bioscience, Inc. (SKYE) | 10-K 2026-03-10 | "In particular, there is intense competition in the obesity and overweight field, especially with the advent of GLP-1 RAs, such as Wegovy, marketed by Novo Nordisk, and Zepbound, marketed by Eli Lilly." |

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | — | — | — | $73.79B | — |
| Next quarter (ends 2026-12-31) | — | — | — | $76.16B | — |
| Current fiscal year (ends 2026-12-31) | — | — | — | $303.47B | — |
| Next fiscal year (ends 2027-12-31) | — | — | — | $307.69B | — |